Truist analyst Jailendra Singh raised the firm’s price target on Evolent Health (EVH) to $16 from $14 and keeps a Buy rating on the shares as part of a broader research note previewing Q2 results for Health Care IT / Digital Health sector names. Despite the strong YTD outperformance in shares, investor sentiment still remains relatively mixed, with the interest level from long-onlies/generalist investors seen as “relatively selective”, the analyst tells investors in a research note. HCIT space has also benefited from the lack of direct tariff exposure and other macro uncertainty as well as renewed capital market activity, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVH:
- Evolent Health’s Positive Outlook: Strong Q2 Performance and Promising Pipeline Growth Justify Buy Rating
- Evolent Health appoints Lim as chief clinical officer, Way as CFO
- Evolent Health news Friday ‘incrementally positive,’ says UBS
- GMS jumps after report of competing suitors, Couchbase gets bought: Morning Buzz
- Evolent Health Amends Credit Agreement for Flexibility